Related references
Note: Only part of the references are listed.Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
Josep M. Llovet et al.
HEPATOLOGY (2021)
Prediction of overall survival in patients with hepatocellular carcinoma treated with Y-90 radioembolization by imaging response criteria
M. Ghosn et al.
DIAGNOSTIC AND INTERVENTIONAL IMAGING (2021)
Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial
Etienne Garin et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)
Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma
Yang Jun Kang et al.
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY (2020)
mRECIST for HCC: Performance and novel refinements
Josep M. Llovet et al.
JOURNAL OF HEPATOLOGY (2020)
Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with 90Y in the SARAH Study
Anne-Laure Hermann et al.
RADIOLOGY (2020)
Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group
Riad Salem et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Five-Years Outcome Analysis of 142 Consecutive Hepatocellular Carcinoma Patients Treated with Doxorubicin Eluting Microspheres 30-60 μm: Results from a Single-Centre Prospective Phase II Trial
K. Malagari et al.
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY (2019)
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle et al.
JOURNAL OF HEPATOLOGY (2018)
Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
Masatoshi Kudo et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2018)
The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level Results From the Global Burden of Disease Study 2015
Tomi Akinyemiju et al.
JAMA ONCOLOGY (2017)
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial
Tim Meyer et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis
Antonio Facciorusso et al.
DIGESTIVE AND LIVER DISEASE (2016)
Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma
Riad Salem et al.
GASTROENTEROLOGY (2016)
Lipiodol Transarterial Chemoembolization for Hepatocellular Carcinoma: A Systematic Review of Efficacy and Safety Data
Riccardo Lencioni et al.
HEPATOLOGY (2016)
Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma
Antonio Facciorusso et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2016)
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial
Riccardo Lencioni et al.
JOURNAL OF HEPATOLOGY (2016)
Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma
Frank T. Kolligs et al.
LIVER INTERNATIONAL (2015)
Randomized Comparison of Selective Internal Radiotherapy (SIRT) Versus Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) for the Treatment of Hepatocellular Carcinoma
Michael B. Pitton et al.
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY (2015)
In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?
Amr El Fouly et al.
LIVER INTERNATIONAL (2015)
Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma
R. Golfieri et al.
BRITISH JOURNAL OF CANCER (2014)
Brivanib as Adjuvant Therapy to Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma: A Randomized Phase III Trial
Masatoshi Kudo et al.
HEPATOLOGY (2014)
Transarterial RAdioembolization versus ChemoEmbolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial
Beatrijs A. Seinstra et al.
TRIALS (2012)
Radioembolization Results in Longer Time-to-Progression and Reduced Toxicity Compared With Chemoembolization in Patients With Hepatocellular Carcinoma
Riad Salem et al.
GASTROENTEROLOGY (2011)
Therapeutic Equivalence in Survival for Hepatic Arterial Chemoembolization and Yttrium 90 Microsphere Treatments in Unresectable Hepatocellular Carcinoma A Two-Cohort Study
Brian I. Carr et al.
CANCER (2010)
Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study
Johannes Lammer et al.
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY (2010)
Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes
Riad Salem et al.
GASTROENTEROLOGY (2010)
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Riccardo Lencioni et al.
SEMINARS IN LIVER DISEASE (2010)
A Comparative Analysis of Transarterial Downstaging for Hepatocellular Carcinoma: Chemoembolization Versus Radioembolization
R. J. Lewandowski et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2009)
Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: Results of an open-label study of 62 patients
Katerina Malagari et al.
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY (2008)
Share Paper
